The current management of DN consists of the control of cardiovascular risk factors, the reduction of albuminuria, the application of angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs), and sodium-glucose cotransporter 2 (SGLT2) inhibitors [7]. The gene discussed is SLC5A2; the disease is liver dysplastic nodule.